论文部分内容阅读
目的观察甘精胰岛素联合诺和龙(瑞格列奈)治疗2型糖尿病的临床疗效。方法选择72例符合WH0诊断标准的2型糖尿病患者,应用甘精胰岛素与诺和龙联合治疗24周,观察空腹血糖、HbA1c、餐后2h血糖。结果甘精胰岛素与诺和龙合用治疗后FBG、PBG、HbA1c均明显下降(P<0.05),低血糖发生率低。结论甘精胰岛素与诺和龙合用,可更好地模拟生理性胰岛素早期分泌,有效降低血糖,临床应用安全有效。
Objective To observe the clinical efficacy of insulin glargine combined with noravone (repaglinide) in the treatment of type 2 diabetes mellitus. Methods 72 patients with type 2 diabetes mellitus who meet the WH0 diagnostic criteria were selected and treated with glargine and noradrenonin for 24 weeks. The fasting blood glucose, HbA1c, and postprandial blood glucose 2h were observed. Results Glargine and Nuo-long combined treatment FBG, PBG, HbA1c were significantly decreased (P <0.05), low incidence of hypoglycemia. Conclusion Glargine combined with Novolin can better simulate the early secretion of physiological insulin and effectively lower blood sugar, which is safe and effective in clinical application.